You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2016
|
| DOI | 10.1186/s40425-016-0158-5 |
| Pubmed ID | |
| Authors |
Hasan Rehman, Ann W. Silk, Michael P. Kane, Howard L. Kaufman |
| Abstract |
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow, and so far has been largely limited to specialized cancer centers. Limiting factors include the intratumoral route of administration, which is unfamiliar to medical oncologists, biosafety concerns related to the use of a live virus in the clinic, and the explosion of other therapeutic strategies now available for the treatment of advanced melanoma. Herein, we review the development of T-VEC, and suggest how it fits into the in the current clinical treatment paradigm, and provide pearls for drug preparation, administration, and monitoring of response to therapy. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 21% |
| Colombia | 1 | 4% |
| Paraguay | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 16 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 83% |
| Scientists | 2 | 8% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 317 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| Unknown | 316 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 74 | 23% |
| Student > Ph. D. Student | 46 | 15% |
| Student > Master | 35 | 11% |
| Researcher | 31 | 10% |
| Student > Doctoral Student | 25 | 8% |
| Other | 37 | 12% |
| Unknown | 69 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 74 | 23% |
| Medicine and Dentistry | 41 | 13% |
| Immunology and Microbiology | 34 | 11% |
| Agricultural and Biological Sciences | 29 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 7% |
| Other | 39 | 12% |
| Unknown | 77 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 633. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2022.
All research outputs
#35,285
of 25,646,963 outputs
Outputs from Journal for Immunotherapy of Cancer
#3
of 3,472 outputs
Outputs of similar age
#668
of 328,706 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 19 outputs
Altmetric has tracked 25,646,963 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,472 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,706 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.